Adequacy of family history taking in ovarian cancer patients: A population-based study

Familial Cancer

Volumn 11, Issue 3, 2012, Pages 343-349

  Van Altena, Anne M ^a   Van Aarle, Sandra ^a   Kiemeney, Lambertus A L M ^a,b   Hoogerbrugge, Nicoline ^a   Massuger, Leon F A G ^a   De Hullu, Joanne A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Netherlands Comprehensive Cancer Organisation The Netherlands   (Netherlands)

Author keywords

Family history taking; Hereditary neoplastic syndromes; Ovarian neoplasms

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER REGISTRY; CANCER RISK; CONTROLLED STUDY; FAMILIAL CANCER; FAMILY HISTORY; FEMALE; GENETIC SCREENING; GROUPS BY AGE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MEDICAL DOCUMENTATION; MEDICAL RECORD REVIEW; OVARY CARCINOMA; POPULATION RESEARCH; PRIORITY JOURNAL; QUESTIONNAIRE; RELATIVE; RISK ASSESSMENT; TEACHING HOSPITAL; VALIDITY;

ADULT; AGE FACTORS; BREAST NEOPLASMS; FAMILY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HOSPITALS; HUMANS; MEDICAL HISTORY TAKING; MEDICAL RECORDS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS, GLANDULAR AND EPITHELIAL; NETHERLANDS; OVARIAN NEOPLASMS; PEDIGREE; QUESTIONNAIRES; RISK ASSESSMENT;

EID: 84870442383     PISSN: 13899600     EISSN: 15737292     Source Type: Journal    
DOI: 10.1007/s10689-012-9518-6     Document Type: Article

References (26)

1. Stratton JF, Pharoah P, Smith SK, Easton D, Ponder BA (1998) A systematic review and meta-analysis of family history and risk of ovarian cancer. Br J Obstet Gynaecol 105(5):493-499
2. Lynch HT, Casey MJ, Snyder CL, Bewtra C, Lynch JF, Butts M et al (2009) Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management. Mol Oncol 3(2):97-137. doi:10.1016/j.molonc.2009.02.004
3. Rubin SC, Blackwood MA, Bandera C, Behbakht K, Benjamin I, Rebbeck TR et al (1998) BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing. Am J Obstet Gynecol 178(4): 670-677
4. Pal T, Permuth-Wey J, Betts JA, Krischer JP, Fiorica J, Arango H et al (2005) BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 104(12):2807-2816. doi:10.1002/cncr.21536
5. Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E et al (2001) Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 68(3):700-710
6. Zhang S, Royer R, Li S, McLaughlin JR, Rosen B, Risch HA et al (2011) Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecol Oncol 121(2):2919-2921. doi:10.1016/j.ygyno. 2011.01.020
7. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72(5):1117-1130. doi:10.1086/375033
8. King MC, Marks JH, Mandell JB (2003) Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302(5645):643-646. doi:10.1126/science.1088759
9. Ramus SJ, Gayther SA (2009) The contribution of BRCA1 and BRCA2 to ovarian cancer. Mol Oncol 3(2):138-150. doi:10.1016/j.molonc.2009.02.001
10. Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C et al (2011) Effect of screening on ovarian cancer mortality: the prostate, lung, colorectal and ovarian (PLCO) cancer screening randomized controlled trial. JAMA 305(22):2295-2303. doi:10.1001/jama.2011.766
11. Woodward ER, Sleightholme HV, Considine AM, Williamson S, McHugo JM, Cruger DG (2007) Annual surveillance by CA125 and transvaginal ultrasound for ovarian cancer in both high-risk and population risk women is ineffective. BJOG 114(12):1500-1509. doi:10.1111/j.1471-0528.2007.01499.x
12. Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B et al (2006) Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA 296(2):185-192. doi:10.1001/jama.296.2.185
13. Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA et al (2002) Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346(21):1609-1615. doi:10.1056/NEJMoa020119
14. Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van't Veer L, Garber JE et al (2002) Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346(21):1616-1622. doi:10.1056/NEJMoa012158
15. Calderon-Margalit R, Paltiel O (2004) Prevention of breast cancer in women who carry BRCA1 or BRCA2 mutations: a critical review of the literature. Int J Cancer 112(3):357-364. doi: 10.1002/ijc.20429
16. Valdez R, Yoon PW, Qureshi N, Green RF, Khoury MJ (2010) Family history in public health practice: a genomic tool for disease prevention and health promotion. Annu Rev Public Health 31:69-87. doi: 10.1146/annurev.publhealth. 012809.103621
17. Murff HJ, Byrne D, Syngal S (2004) Cancer risk assessment: quality and impact of the family history interview. Am J Prev Med 27(3):239-245. doi:10.1016/j.amepre.2004.05.003
18. Foo W, Young JM, Solomon MJ, Wright CM (2009) Family history? The forgotten question in high-risk colorectal cancer patients. Color Dis 11(5):450-455. doi:10.1111/j.1463-1318.2009.01898.x
19. Trano G, Wasmuth HH, Sjursen W, Hofsli E, Vatten LJ (2009) Awareness of heredity in colorectal cancer patients is insufficient among clinicians: a Norwegian population-based study. Color Dis 11(5):456-461. doi:10.1111/j.1463- 1318.2009.01830.x
20. van Dijk DA, Oostindier MJ, Kloosterman-Boele WM, Krijnen P, Vasen HF (2007) Family history is neglected in the work-up of patients with colorectal cancer: a quality assessment using cancer registry data. Fam Cancer 6(1):131-134. doi:10.1007/s10689-006-9114-8
21. Ziogas A, Anton-Culver H (2003) Validation of family history data in cancer family registries. Am J Prev Med 24(2):190-198. doi:10.1016/S0749- 3797(02)00593-7
22. Murff HJ, Spigel DR, Syngal S (2004) Does this patient have a family history of cancer? An evidence-based analysis of the accuracy of family cancer history. JAMA 292(12):1480-1489
23. Douglas FS, O'Dair LC, Robinson M, Evans DG, Lynch SA (1999) The accuracy of diagnoses as reported in families with cancer: a retrospective study. J Med Genet 36(4):309-312. doi:10.1016/j.ejca.2003.09.016
24. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN et al (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376(9737): 235-244. doi:10.1016/S0140-6736(10)60892-6
25. Ziogas A, Horick NK, Kinney AY, Lowery JT, Domchek SM, Isaacs C et al (2011) Clinically relevant changes in family history of cancer over time. JAMA 306(2):172-178. doi:10.1001/jama.2011.955
26. Malander S, Ridderheim M, Masback A, Loman N, Kristoffersson U, Olsson H et al (2004) One in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2 mutations: results of a prospective study in Southern Sweden. Eur J Cancer 40(3):422-428. doi:10.1016/j.ejca.2003.09.016